ImmunityBio (IBRX) shares jumped 30% after the European Commission granted conditional marketing authorisation for its bladder cancer drug 'Anktiva'. The approval applies to BCG-unresponsive bladder cancer but requires the company to submit further data. The drug is now approved in 33 countries, including the US. Wall Street and retail investors are eyeing further gains.